Table 2.

rbsAbs in clinical trials

Name (format)	Target 1	Target 2	Phase	Refs
MDX-447 [F(ab′) 2]	EGFR	FcγRI	I	[133]
MM-111 (trimeric scFv)	ErbB2	ErbB3	I–II	[134]
DT2219ARL (dimeric scFv)	CD19	CD22/DT390	I	[22]
TF2 (Tri-Fab)	CEA	HSG	I–II	[135]
rM28 (scAb)	Melanoma-associated proteoglycan	CD28	I–II	[136]
MT103 (BiTE)	CD19	CD3	I–II	[137]
MT110 (BiTE)	EpCAM	CD3	I	[138]
SAR156597 (Tetravalent bispecific tandem Ig)	IL-4	IL-13	I	[139]
AFM13 (TandAb)	CD30	CD16A	I	[140]
MEHD-7945A (bsmAb)	EGFR	HER3	I–II	[141]
Ozoralizumab (Trivalent bispecific nanobody)	TNF	HSA	II	[142]

Adapted from [143].

Abbreviations: HSA, Human Serum Albumin; TNF, tumor necrosis factor.